‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.

Live updates

1. 1h ago

   Cancer Vaccines Advance After Successful Melanoma Studies

   An effective cancer vaccine has been developed following successful clinical trials involving a personalized mRNA melanoma vaccine and Keytruda by drug makers Merck and Cambridge-based Moderna. The findings mark a significant step forward for personalized cancer treatment, though further research and reviews remain necessary before the vaccine achieves widespread availability. Meanwhile, the National Institutes of Health announced plans to invest nearly two hundred million dollars into developing cancer vaccines beginning in December. Scientists now face the question of how broadly the successful melanoma approach can work and how to efficiently deliver these treatments to patients.

   Why it matters

   After a century of failure, recent clinical trials by Merck and Moderna demonstrate that personalized mRNA technology can significantly reduce the risk of melanoma recurrence. These developments have drawn substantial financial backing, including a massive investment from the National Institutes of Health slated to start in December. Researchers are now working to determine the broader applications of this technology across different types of cancer.

   What is confirmed

   • Drug makers Merck and Cambridge-based Moderna announced promising clinical trial results for a personalized mRNA melanoma vaccine used alongside Keytruda.
   • The National Institutes of Health stated it will pour nearly $200 million into developing cancer vaccines starting in December.

   Still unconfirmed

   • Moderna investors should brace for more whiplash following recent data leaks and trial updates.

   What to watch next

   • The rollout of the National Institutes of Health funding commitment toward cancer vaccine development in December.
   • Further research and reviews regarding the widespread availability of the Moderna-Merck melanoma vaccine.
   • Broader clinical testing to see if the successful melanoma vaccine approach works for other cancer types.
   Sources used for this update (12)

   1. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
   2. WSJ — Moderna Investors Should Brace for More Whiplash
   3. Fierce Biotech — ‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
   4. www.statnews.com — What's next for cancer vaccines after successful melanoma study
   5. STAT — Cancer vaccines are finally here. How do we get them to patients?
   6. The Boston Globe — ‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
   7. Barron's — Moderna’s CEO Gives an Inside Look at the Biotech’s New Era
   8. www.bostonglobe.com — Melanoma vaccine: A Dana-Farber doctor on cancer vaccine news
   9. www.philstockworld.com — ‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the ...
   10. biztoc.com — ‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the ...
   11. theprint.in — Cancer vaccines move a step forward. Moderna-Merck trial ...
   12. www.uchealth.org — Personalized mRNA melanoma vaccine with Keytruda shows ...
   confidence 95%